Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2020.03.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced Recovery After Surgery for patients undergoing radical cystectomy: Surgeons' perspectives and recommendations ten years after its implementation.
Eur J Surg Oncol
December 2024
Oncologic Minimally Invasive Urology and Andrology Unit, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy.
Background And Objectives: Enhanced Recovery After Surgery (ERAS) guidelines for Radical Cystectomy (RC) were published over ten years ago. Aim of this systematic review is to update ERAS recommendations for patients undergoing RC and to give an expert opinion on the relevance of each single ERAS item.
Methods: A systematic review was performed to identify the impact of each single ERAS item on RC outcomes.
Robot-assisted Kidney Transplantation: The 8-year European Experience.
Eur Urol
January 2025
Department of Urology, Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.
Background And Objective: Evidence regarding perioperative results and long-term functional outcomes of robotic-assisted kidney transplantation (RAKT) is limited. We evaluated perioperative surgical results and long-term functional outcomes of RAKT in patients receiving kidney transplants from living donors.
Methods: This retrospective analysis is based on a prospective multicenter cohort study conducted from July 2015 to October 2023 across ten European centers.
The role of intravesical chemotherapy following nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis.
Urol Oncol
November 2024
Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
Article Synopsis
- Intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy occurs in 22% to 47%, prompting the need for effective intravesical chemotherapy, which remains underused due to safety and efficacy concerns.
- A systematic review analyzed 18 studies with 2,483 patients, finding that intravesical chemotherapy significantly lowered the risk of recurrence at 12 months (OR=0.46) and 24 months (OR=0.41) after surgery.
- The study highlighted a favorable safety profile for intravesical chemotherapy, showing only 9% minor and 0.9% major complications, while the optimal instillation methods require further investigation.
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.
Target Oncol
November 2024
Department of Urology, The Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Context: Adjuvant immune checkpoint inhibitors (ICIs) have recently emerged as guideline-recommended treatments of high-risk muscle-invasive urothelial carcinoma (MIUC). However, there is limited evidence regarding the optimal candidates and the differential efficacy of adjuvant ICI regimens.
Objective: To synthesize and compare the efficacy and safety of adjuvant ICIs for high-risk MIUC using updated data from phase III randomized controlled trials.
Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer.
Clin Genitourin Cancer
December 2024
Clinica Luganese Moncucco, Lugano, Switzerland; Sant'Anna Clinic, Swiss Medical Group, Sorengo, Switzerland.
Objective: Sparse data exist on the impact of upper urinary tract (UUT) decompression on the risk of UUT recurrence in patients with bladder cancer (BCa). This study aims to evaluate whether Double J stenting (DJS) can increase the risk of UUT recurrence compared to percutaneous nephrostomy (PCN) placement.
Materials And Methods: We retrospectively analyzed data from 1550 patients with cTa-T3NanyM0 BCa who underwent radical cystectomy (RC) between at 12 tertiary care centers (1990-2020).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!